Treatment for Pre-symptomatic Spinal Muscular Atrophy Patients Granted FDA Priority Review
PTC Therapeutics Inc. has just announced that their supplemental new drug application for Evrysdi (risdiplam) has been given priority review by the FDA. The aim is to expand the indication…